Pentamethonium and Hexamethonium Iodide in Vascular Disease and Hypertension

The clinical potentialities of hexamethonium iodide (C6) in producing ganglionic block were first reported by Paton and Zaimis (1948a, 1948b), who stated that it possessed greater potency and longer duration of action than tetra- ethylammonium bromide (T.E.A.B.). Preliminary obser- vations of the effect of pentamethonium iodide (CS) in man were made by Clinical effects of C5 as a vasodilator were reported by Arnold and Rosenheim (1949) and by